Corporate Offices
Technology
Dogwood Therapeutics is a development-stage biotechnology company focused on advancing novel therapeutics for pain and neorpathy
Diseases
Dogwood is working on significant unmet medical needs in chemotherapeutic induced neuropathic pain (CINP), peripheral neuropathy (CIPN), and fibromyalgia.
Clinical Trials
Dogwood is evaluating the safety and effectiveness of Halneuron (HAL) vs placebo in people with established neuropathy due to their chemotherapy.
Breakthrough Therapeutics for Pain and Neuropathy
.png)
Non-Opioid Pain Management
Dogwood’s Lead Candidate Halneuron® represents a breakthrough in painkiller technology:
-
No evidence of addiction, withdrawal symptoms, or euphoria
-
No build of up of tolerance overtime
-
Clinical evidence demonstrating long duration of pain relief with minimal, mild, and temporary side effects
-
Tested in over 700 people in clinical trials
CINP
CINP Chemotherapy treatments can cause peripheral neuropathy by damaging the nerves in the extremities.
Diseases
.png)
CIPN
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent complication of cancer chemotherapy treatment.
